Effects of serelaxin in subgroups of patients with acute heart failure: Results from RELAX-AHF

European Heart Journal

Volumn 34, Issue 40, 2013, Pages 3128-3136

  Metra, Marco ^a   Ponikowski, Piotr ^b   Cotter, Gad ^c   Davison, Beth A ^c   Felker, G Michael ^d   Filippatos, Gerasimos ^e   Greenberg, Barry H ^f   Hua, Tsushung A ^g   Severin, Thomas ^g   Unemori, Elaine ^h   Voors, Adriaan A ⁱ   Teerlink, John R ^j  

^a UNIVERSITY OF BRESCIA   (Italy)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Momentum Research Inc   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h Novartis Pharma AG ^*  (United States)

ⁱ UNIVERSITY OF GRONINGEN   (Netherlands)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Acute heart failure; Mortality; Serelaxin; Subgroups

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; NITRATE; PLACEBO; SERELAXIN;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR THERAPEUTIC DEVICE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPNEA; FEMALE; GEOGRAPHIC DISTRIBUTION; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HOSPITAL READMISSION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RACE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

ACUTE HEART FAILURE; MORTALITY; SERELAXIN; SUBGROUPS;

ACUTE DISEASE; ADULT; AGED; CARDIOTONIC AGENTS; CAUSE OF DEATH; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; RELAXIN; TREATMENT OUTCOME;

EID: 84890096177     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht371     Document Type: Article

References (28)

1. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L, International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:3958-3968.
2. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA, Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007;116:1482-1487.
3. Abrahamsson P, Swedberg K, Borer JS, Böhm M, Kober L, Komajda M, Lloyd SM, Metra M, Tavazzi L, Ford I. Risk following hospitalization in stable chronic systolic heart failure. Eur J Heart Fail 2013;15:885-891.
4. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure:A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation; doi:10.1161/?CIR.0b013e31829e8776. Published online ahead of print 5 June 2013.
5. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pina IL, Ponikowski P, Sabbah HN, Teerlink JR, Udelson JE, YancyCW, Zannad F, Gheorghiade M, International AHFSWorking Group. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 2010;3:314-325.
6. Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors AA, Teerlink JR, Felker GM, Metra M, Cotter G. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 2009;14:321-329.
7. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 2010;7:48-58.
8. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M, RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39.
9. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIB study. Lancet 2009;373:1429-1439.
10. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink Jr. RELAX-AHF Investigators. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61:196-206.
11. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 2013;61:391-403.
12. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008;10:165-169.
13. Cotter G, Moshkovitz Y, Milovanov O, Salah A, Blatt A, Krakover R, Vered Z, Kaluski E. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail 2002;4:227-234.
14. Ponikowski P, Metra M, Teerlink JR, Unemori E, Felker GM, Voors AA, Filippatos G, Greenberg B, Teichman SL, Severin T, Mueller-Velten G, Cotter G, Davison BA. Design of the relaxin in acute heart failure study. Am Heart J 2012;163:149-155 e141.
15. Packer MCW, Fisher L, Massie BM, Teerlink JT, Young J, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T. Effect of levosimendan on the short-Term clinical course of patients with acutely decompensated heart failure. J Am Coll Cardiol Heart Fail 2013;1:8.
16. Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V, Mebazaa A. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J 2013; 34:57-67.
17. Peacock WF, Fonarow GC, Emerman CL, Mills RM, Wynne J, Committee ASA, Investigators, Adhere Study G. Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in adhere. Cardiology 2007;107: 44-51.
18. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. New Engl J Med 2011;365:32-43.
19. Kociol RD, Horton JR, FonarowGC, Reyes EM, Shaw LK, O'Connor CM, FelkerGM, Hernandez AF. Admission, discharge, or change in B-Type natriuretic peptide and long-Term outcomes: data from organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF) linked to medicare claims. Circ Heart Fail 2011;4:628-636.
20. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824-839.
21. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.
22. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M. SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007;297:1883-1891.
23. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan I. Short-Term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 2007;297: 1332-1343.
24. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I. VERITAS Investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-2019.
25. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC, PROTECT Investigators and Committees. Rolofylline, an adenosine a1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-1428.
26. Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, Aranda JM Jr, AbrahamWT, Smart FW, Stevenson LW, Kueffer FJ, Bourge RC. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008;118:1433-1441.
27. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-1069.
28. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002;21:2917-2930.